Ethical, social, and legal dimensions of screening for human genetic disease / editor, Daniel Bergsma ; Genetics Research Group of the Institute of Society, Ethics and the Life Sciences.

Date:
1974
Catalogue details

Licence: Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)

Credit: Ethical, social, and legal dimensions of screening for human genetic disease / editor, Daniel Bergsma ; Genetics Research Group of the Institute of Society, Ethics and the Life Sciences. Source: Wellcome Collection.

    278/288 (page 266)
    268 SUBJECT INDEX Hyperlipidemia, 47,86 dommantly inherited, 88 primary familial, 87 Hyperlipoproteinemia type II, 205 frequency, 205 Hypertension defming the diseased state, 109 detection carrier detection test, 112 definitive diagnosis, 111 identification of prehypertensives, 112 effects of reducing blood pressure, 110 empiric risks in, 110 genetic basis for, 108 imperatives of early treatment, 110 pathologies associated with, 110 polygenic etiology of, 107,108 results of therapeutic intervention. 111 screening, cost-benefits of, 112 guidelines, 112 in black populations. 111 rationale for. 111 research, 112 therapy, 110,118 Illness attitudes toward, 171 definition of, 47 sick role, 171 social acceptability of, 171 Implied consent, rules for, 65 Immune responsiveness, 6 Immunization, relevance to genetic controls, 196 Immunodeficiency diseases, 6 Immunoglobulin, 6 classes,5 Incidence, definition of, 126 Infanticide, 221 Informed consent, 19,20,132 attainability of, 138 attitudes regarding, 138 contents of, 62 disclosure of риф08е, risks, benefits, 137 feasibility of, 138 forms of, 139 in carrier screening programs, 137 in voluntary screening programs, 60 requirements for, 60 questionnaires, use of, 139,151 Inheritance modes of, 102 multifactorial, 101 polygenic, 101 Institute of Society, Ethics and Life Sciences, Genetics Research Group, 86 Institutions for mentally retarded, population in, 129 Intrauterine diagnosis, 155, 191, 193, 227,236 Isotopes, 10 Karyotyping for trisomy 21,46 Ketotic hyperglycinemia, 10 Klinefelter syndrome, 129 Legislation, justification of,l Lipid abnormalities, 87 Mandatory screening (see compulsory) Maple syrup disease, 10,15, 32, 33 Mass screening anxiety generated by, 45 automated technics, 11 compulsory, 1, costs, 9,14 criteria for, 85,86 for immune responsiveness, 6 for immunodeficiency diseases, 6 Massachusetts Metabolic Diseases Screening Program, 9-11,14, 31 private agency programs, 57 criteria for regulation, 58 limitations imposed on, 58 program establishment, 10,13 public programs, 57 constitutional limitations, 57, 66, 69 rationales for, 85 research potential, 12,20 scientific criteria for, 7